ReachMD CME
by ReachMD
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Weekly cadence·368 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHosts
Recent guests
Recent episodes
No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
Jul 14, 2026
13m 15s
Closing the Gaps: Global Implementation of Lipid Guidelines
Jun 30, 2026
1h 00m 00s
Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF
Jun 23, 2026
17m 15s
Unblocking Clinical Inertia: The CMI Era in oHCM Care
Jun 16, 2026
39m 00s
Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
Jun 1, 2026
14m 15s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/14/26 | chronic kidney diseasediabetes+4 | Dr. Katherine TuttleDr. Brendon Neuen | ERAReachMD+1 | — | chronic kidney diseaseCKD+5 | — | 13m 15s | ||
| 6/30/26 | lipid guidelinescardiovascular care+3 | — | ReachMD | — | CMElipid management+3 | — | 1h 00m 00s | ||
| 6/23/26 | nonsteroidal MRAsheart failure+4 | Muthu VaduganathanMichael Böhm+1 | finerenoneSGLT2 inhibitors+1 | — | nonsteroidal MRAsheart failure+6 | — | 17m 15s | ||
| 6/16/26 | obstructive hypertrophic cardiomyopathyclinical inertia+3 | — | cardiac myosin inhibitorsReachMD+1 | oHCMheart failure | CME creditsoHCM care+4 | — | 39m 00s | ||
| 6/1/26 | advanced urothelial carcinomaNCCN Guidelines+3 | — | NCCN | — | CMEurothelial carcinoma+6 | — | 14m 15s | ||
| 6/1/26 | HER2 expressionsolid tumors+4 | Dr. Kathleen Moore | trastuzumab deruxtecan (T-DXd)HER2+3 | — | HER2solid tumors+5 | — | 18m 00s | ||
| 5/29/26 | perioperative immunotherapyhead and neck cancer+4 | — | ReachMDHNSCC | — | CMEimmunotherapy+5 | — | 4m 45s | ||
| 5/29/26 | immunotherapyperioperative care+4 | — | immunotherapyReachMD+1 | — | CMEimmunotherapy+6 | — | 5m 30s | ||
| 5/29/26 | perioperative careimmunotherapy+4 | — | immunotherapymultimodality therapy+3 | — | CMEperioperative data+5 | — | 5m 15s | ||
| 5/29/26 | perioperative immunotherapyhead and neck cancer+3 | — | ReachMDBefore the Scalpel: Identifying Candidates for Perioperative Immunotherapy | locally advanced head and neck squamous cell carcinoma (HNSCC) | immunotherapyHNSCC+3 | — | 5m 15s | ||
| 4/24/26 | systemic mastocytosisclinical decisions+4 | — | ReachMD | — | CMEsystemic mastocytosis+4 | — | 14m 00s | ||
| 4/20/26 | glaucoma managementocular surface resilience+4 | — | preservative-free optionstear-restorative+3 | — | glaucomaocular surface+5 | — | 1h 01m 30s | ||
| 4/15/26 | retinal diseasestreatment options+3 | — | ReachMD | — | CME creditsretina+3 | — | 32m 30s | ||
| 4/10/26 | retinal diseasesinjection therapies+3 | — | ReachMDThe Focused Sight Initiative | age-related macular degenerationdiabetic retinopathy+1 | CME creditsretina specialists+3 | — | 57m 45s | ||
| 4/7/26 | pediatric patientsC3 glomerulopathy+4 | — | ReachMDC3 Glomerulopathy+2 | — | C3 glomerulopathypediatric nephrology+5 | — | 14m 15s | ||
| 3/31/26 | antihistaminesCKD-associated pruritus+3 | Antoine LanotGil Yosipovitch | ReachMDCKD+1 | — | antihistaminesCKD+5 | — | 16m 00s | ||
| 3/31/26 | KIT-targeted tyrosine kinase inhibitorsindolent systemic mastocytosis+5 | — | avapritinibelenestinib+2 | — | KIT inhibitorstyrosine kinase inhibitors+8 | — | 14m 15s | ||
| 3/31/26 | head and neck cancerimmune checkpoint inhibition+3 | Dr. UppaluriDr. Lee | PD-L1ReachMD+2 | HNSCC | HNSCCCME+7 | — | 15m 30s | ||
| 3/26/26 | mineralocorticoid receptor antagonismheart failure+5 | Maria PabonRobert Mentz | ReachMD | — | mineralocorticoid receptor antagonismheart failure+5 | — | 15m 00s | ||
| 3/26/26 | obstructive hypertrophic cardiomyopathymanagement strategies+3 | — | cardiac myosin inhibitorsReachMD+1 | — | oHCMbeta-blockers+5 | — | 4m 30s |
Showing 20 of 20
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.